Larimar Therapeutics, Inc. ZA71.F Stock
Larimar Therapeutics, Inc. Price Chart
Larimar Therapeutics, Inc. ZA71.F Financial and Trading Overview
| Larimar Therapeutics, Inc. stock price | 6.7 EUR |
| Previous Close | 3.38 EUR |
| Open | 3.04 EUR |
| Bid | 3.04 EUR x N/A |
| Ask | 3.16 EUR x N/A |
| Day's Range | 3.04 - 3.04 EUR |
| 52 Week Range | 1.53 - 6.15 EUR |
| Volume | 430 EUR |
| Avg. Volume | 20 EUR |
| Market Cap | 133.1M EUR |
| Beta (5Y Monthly) | 0.190439 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.88 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ZA71.F Valuation Measures
| Enterprise Value | 39.97M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.2382892 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -1.143 |
Trading Information
Larimar Therapeutics, Inc. Stock Price History
| Beta (5Y Monthly) | 0.190439 |
| 52-Week Change | 76.04% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 6.15 EUR |
| 52 Week Low | 1.53 EUR |
| 50-Day Moving Average | 3.86 EUR |
| 200-Day Moving Average | 3.87 EUR |
ZA71.F Share Statistics
| Avg. Volume (3 month) | 20 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 43.27M |
| Float | 20.75M |
| Short Ratio | N/A |
| % Held by Insiders | 1.61% |
| % Held by Institutions | 90.13% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -23.19% |
| Return on Equity (ttm) | -40.32% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -34962000 EUR |
| Net Income Avi to Common (ttm) | -32938000 EUR |
| Diluted EPS (ttm) | -0.98 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 111.52M EUR |
| Total Cash Per Share (mrq) | 2.58 EUR |
| Total Debt (mrq) | 5.25M EUR |
| Total Debt/Equity (mrq) | 4.94 EUR |
| Current Ratio (mrq) | 14.165 |
| Book Value Per Share (mrq) | 2.455 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -27587000 EUR |
| Levered Free Cash Flow (ttm) | -15477500 EUR |
Profile of Larimar Therapeutics, Inc.
| Country | Germany |
| State | PA |
| City | Bala Cynwyd |
| Address | Three Bala Plaza East |
| ZIP | 19004 |
| Phone | 844 511 9056 |
| Website | https://www.larimartx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 26 |
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania.
Q&A For Larimar Therapeutics, Inc. Stock
What is a current ZA71.F stock price?
Larimar Therapeutics, Inc. ZA71.F stock price today per share is 6.7 EUR.
How to purchase Larimar Therapeutics, Inc. stock?
You can buy ZA71.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Larimar Therapeutics, Inc.?
The stock symbol or ticker of Larimar Therapeutics, Inc. is ZA71.F.
Which industry does the Larimar Therapeutics, Inc. company belong to?
The Larimar Therapeutics, Inc. industry is Biotechnology.
How many shares does Larimar Therapeutics, Inc. have in circulation?
The max supply of Larimar Therapeutics, Inc. shares is 64.67M.
What is Larimar Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Larimar Therapeutics, Inc. PE Ratio is now.
What was Larimar Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Larimar Therapeutics, Inc. EPS is -0.88 EUR over the trailing 12 months.
Which sector does the Larimar Therapeutics, Inc. company belong to?
The Larimar Therapeutics, Inc. sector is Healthcare.